We are committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Our R&D efforts are focused on four key therapeutic areas: Gastroenterology (GI), Critical Illness, Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
Brand name |
Generic name |
Gastroenterology |
|
Dexilant |
Dexlansoprazole |
Takepron |
Lansoprazole |
Pantoloc |
Pantoprazole |
Faktu |
Policresulen/Cinchocaine |
Entyvio |
Vedolizumab |
Mezavant |
Mesalazine |
Critical Illness |
|
Adcetris |
Brentuximab vedotin |
Alunbrig |
Brigatinib |
Enantone |
Leuprorelin acetate |
Ninlaro |
Ixazomib citrate |
Rare Diseases |
|
Advate |
Octocog alfa Antihemophilic Factor (Recombinant) |
Agrylin |
Anagrelide |
Feiba |
Anti-inhibitor coagulant complex |
Kiovig |
Human Normal Immunoglobin (IVIg) |
Neuroscience |
|
Vyvanse |
Lisdexamfetamine Dimesylate |
Others |
|
Fosrenol |
Lanthanum Carbonate |
Gutron |
Midodrine |
Ubretid |
Distigmine |
C-APROM/HK/CORP/0063 (01/2021)